About NCIMB
NCIMB is a company based in United Kingdom founded in 1982.. NCIMB has raised $2.27 million across 3 funding rounds from investors including Maven Capital Partners, European Union and The Scottish National Investment Bank. NCIMB offers products and services including Culture Collection, Microbiology and Lab Services, Ecotoxicity Testing, Preservation and Storage, and Quality Control Products. NCIMB operates in a competitive market with competitors including Evelo Biosciences, PathogenDX, BioAgilytix, Advion and Tentamus, among others.
- Headquarter Scotland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ncimb Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.27 M (USD)
in 3 rounds
-
Latest Funding Round
$2.27 M (USD), Series A
Apr 29, 2025
-
Investors
Maven Capital Partners
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NCIMB
NCIMB offers a comprehensive portfolio of products and services, including Culture Collection, Microbiology and Lab Services, Ecotoxicity Testing, Preservation and Storage, and Quality Control Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Manages bacterial strains for research and biotechnology.
Detects and identifies microorganisms for various applications.
Conducts microbial tests for ecotoxicity assessment.
Offers biological material storage and patent deposits.
Provides microorganisms for quality control testing.
Funding Insights of NCIMB
NCIMB has successfully raised a total of $2.27M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.27 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $2.3M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Series A - NCIMB | Valuation |
investors |
|
| Dec, 2020 | Amount | Grant - NCIMB | Valuation |
investors |
|
| Jun, 2008 | Amount | Unspecified - NCIMB | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NCIMB
NCIMB has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Maven Capital Partners, European Union and The Scottish National Investment Bank. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for private equity investments.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Development investments are channeled into Scottish enterprises and projects.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NCIMB
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NCIMB
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ncimb Comparisons
Competitors of NCIMB
NCIMB operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, PathogenDX, BioAgilytix, Advion and Tentamus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Provider of DNA-based pathogen testing kits
|
|
| domain | founded_year | HQ Location |
Large-molecule bioanalysis is provided for biologics and biosimilars development.
|
|
| domain | founded_year | HQ Location |
Microfluidics and mass spectrometry products are provided for clinical research.
|
|
| domain | founded_year | HQ Location |
Analytical and quality assurance services are provided for diverse industries.
|
|
| domain | founded_year | HQ Location |
Analytical services are provided for microbiology, chemistry, and bioprocesses sectors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about NCIMB
When was NCIMB founded?
NCIMB was founded in 1982 and raised its 1st funding round 26 years after it was founded.
Where is NCIMB located?
NCIMB is headquartered in United Kingdom. It is registered at Scotland, United Kingdom.
Is NCIMB a funded company?
NCIMB is a funded company, having raised a total of $2.27M across 3 funding rounds to date.
What does NCIMB do?
NCIMB was founded in 1982 in Scotland as a provider of biorepository and microbial culture collection services. Microbiology, chemical analysis, and biomaterial storage are offered to clients in pharmaceuticals, personal care, oil and gas, food, agriculture, environmental sectors, and academia. Operations include microbial identification, patent deposits, freeze-drying, oilfield microbiology, toxicity testing, analytical services, and RD support, with a focus on industrial and academic needs.
Who are the top competitors of NCIMB?
NCIMB's top competitors include PathogenDX, Alderley Analytical and BioAgilytix.
What products or services does NCIMB offer?
NCIMB offers Culture Collection, Microbiology and Lab Services, Ecotoxicity Testing, Preservation and Storage, and Quality Control Products.
Who are NCIMB's investors?
NCIMB has 4 investors. Key investors include Maven Capital Partners, European Union, The Scottish National Investment Bank, and E-Synergy.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.